IOA-237 / iOnctura - LARVOL DELTA

[VIRTUAL] IOA-237 - A potent anti-CD73 mAb demonstrates monotherapeutic and combination efficacy in solid tumor models (AACR 2021) - "Best-in-class potential was confirmed with head-to-head comparison against a clinical stage anti-CD73 mAb, MEDI9447. These data indicate the potential of IOA-237 in monotherapeutic and combination therapeutic approaches and warrants further development. Additional in vitro and in vivo efficacy studies are ongoing and non-clinical safety studies are being planned."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • NT5E